Implementation and challenges of prehabilitation in gastrointestinal oncology: A national cross-sectional survey in France
Prehabilitation in GI oncology is emerging but remains inconsistently applied across France. To scale these interventions equitably and effectively, national guidelines, enhanced coordination and institutional support are essential. Integration with existing perioperative pathways like ERAS and increased psychological support are also needed to improve patient outcomes. Only one center in our sample offered systematic psychological support.
Authors
- Bruno Raynard (ORCID: https://orcid.org/0000-0001-7831-2440)
- Cindy Neuzillet
- Sandrine Hiret (ORCID: https://orcid.org/0000-0002-3789-8171)
- Damien Vansteene (ORCID: https://orcid.org/0000-0002-4440-0626)
- Marc Hilmi (ORCID: https://orcid.org/0000-0003-4762-6740)
- Florence Carrouel (ORCID: https://orcid.org/0000-0002-6823-1636)
- Eva Ester Molina Beltran
- Claude Dussart (ORCID: https://orcid.org/0000-0002-1091-9139)
- Matthieu Delaye (ORCID: https://orcid.org/0000-0002-2435-4757)
- Nora Dollet Nedellec
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- Lyon College (US)
- Université de Versailles Saint-Quentin-en-Yvelines (FR)
- AgroParisTech (FR)
- Institut Gustave Roussy (FR)
- Communauté urbaine de Lyon (FR)
- Institut de Cancérologie de l'Ouest (FR)
- Institut Curie (FR)
Publication Details
- Journal
- Clinical Nutrition ESPEN
- Published
- 2025-09-27
- DOI
- https://doi.org/10.1016/j.clnesp.2025.09.018
- Primary Topic
- Cancer survivorship and care
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Les Laboratories Pierre Fabre
- Mylan
- Eisai
- Astellas Pharma
- Servier